CDC Panel Backs Pfizer’s Maternal RSV Vaccine But Leaves Room For AstraZeneca/Sanofi’s Beyfortus

 
• By Sue Sutter

Abrysvo is recommended for use in pregnant people 32-36 weeks gestation if administered from September to January. For infants whose mothers were not vaccinated in this window, nirsevimab is recommended for prevention of respiratory syncytial virus infection.

Threading the needle
ACIP threaded the needle in deciding when Abrysvo and nirsevimab should be used. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers